Bausch Health Companies Inc. (TSX:BHC)
Canada · Delayed Price · Currency is CAD | Market Cap | 2.81B +17.2% |
| Revenue (ttm) | 14.70B +8.2% |
| Net Income | -1.69B |
| EPS | -4.54 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 1.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 430,175 |
| Average Volume | 461,091 |
| Open | 7.53 |
| Previous Close | 7.56 |
| Day's Range | 7.34 - 7.54 |
| 52-Week Range | 6.06 - 11.97 |
| Beta | 0.42 |
| RSI | 48.85 |
| Earnings Date | Apr 29, 2026 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States... [Read more]
News
Bausch Health Companies Transcript: RBC Capital Markets Global Healthcare Conference 2026
Management highlighted sustained growth across key franchises, strong execution in China and Solta, and a focus on maximizing cash flow through 2027. The company is preparing for post-XIFAXAN transition, managing legal risks, and considering options to monetize its BLCO stake.
Bausch Health Announces 2026 Annual Meeting of Shareholder Results
LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders (...
Bausch Health Companies Transcript: Barclays 30th Annual Leveraged Finance Conference 2026
Twelve consecutive quarters of growth were driven by strong Salix and Solta performance, with AI-powered strategies sustaining XIFAXAN's momentum. Liquidity is robust, with plans to monetize B&L shares post-2028, and guidance incorporates regulatory and global risks.
Bausch Health Companies Transcript: AGM 2026
The meeting confirmed quorum, introduced ten director nominees, and presented three voting items: director elections, executive compensation, and auditor appointment. All proposals passed by majority vote, and no shareholder questions were received.
Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...
Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference
LAVAL, QC, May 13, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive Vice Preside...
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
LAVAL, QC, May 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate in a fireside chat at the Barclays 30th Ann...
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European l...
Bausch Health Companies Earnings Call Transcript: Q1 2026
Revenue and adjusted EBITDA grew double digits year-over-year, led by Salix and Solta, with strong cash flow and reduced net debt. Guidance for 2026 is reaffirmed, including minimal expected tariff impact, and AI-driven initiatives are boosting commercial and R&D productivity.
Bausch Health Companies Slides: Q1 2026
Bausch Health Companies has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Bausch Health Companies Earnings release: Q1 2026
Bausch Health Companies released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Bausch Health Companies Quarterly report: Q1 2026
Bausch Health Companies has published its Q1 2026 quarterly earnings report on April 29, 2026.
Bausch Health reports Q1 non-GAAP EPS 78c, consensus 69c
Reports Q1 revenue $2.52B, consensus $2.41B. “Our Q1 performance marks twelve consecutive periods of year-over-year growth in revenue, adjusted EBITDA for Bausch Health (BHC) excluding Bausch + Lomb, ...
Bausch Health sees 2026 revenue $10.67B-$10.92B, consensus $10.68B
16:17 EDT Bausch Health (BHC) sees 2026 revenue $10.67B-$10.92B, consensus $10.68B
BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS
First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health of $1,423...
Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Ophthalmo...
Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering
The skin recovery emulsion for dry, sensitive, or stressed skin is now available through select online channels LAVAL, QC, April 14, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BH...
Bausch Health Companies Proxy statement: Proxy filing
Bausch Health Companies filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Bausch Health Companies Proxy statement: Proxy filing
Bausch Health Companies filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. ...
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European comme...
Bausch Health to Announce First Quarter 2026 Results on April 29, 2026
LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Hea...
Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program
Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026 LAVAL, QC, March 26, 2026 /PRNewswire/ -- Bausch Health Companies I...
Bausch Health price target lowered to $7 from $8 at Barclays
Barclays analyst Glen Santangelo lowered the firm’s price target on Bausch Health (BHC) to $7 from $8 and keeps an Equal Weight rating on the shares post the Q4 report.
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
LAVAL, QC, Feb. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today...